Skip to main content
. 2016 Jun 14;7(29):46014–46027. doi: 10.18632/oncotarget.10014

Figure 6. Ikaros deletion results in changes of SH2B3 and IL7R expression in primary B-ALL cells.

Figure 6

A-B. comparison of SH2B3 (A) and IL7R (B) in patients with or without Ikaros deletion; C-D. Effect of CK2 inhibitor (TBB) on expression of SH2B3 and IL7R in primary B-ALL cells with TBB treatment for 2 days.